Sionna Therapeutics

Child with cystic fibrosis on ventilator
#Cystic fibrosis #Gene mutation #Phase I trial #Sionna Therapeutics

Two Phase I trials to assess NBD1 stabilisers for cystic fibrosis

The first subjects have been dosed in two separate Phase I clinical trials evaluating the safety, tolerability, and pharmacokinetics of Sionna Therapeutics’ SION-719 and SION-451 in healthy volunteers. SION-719 and SION-451 are product candidates from the company’s series of highly potent nucleotide-binding domain 1 (NBD1) stabilisers… Read More

#News